Literature DB >> 33442507

Purification of recombinant human chemokine CCL2 in E. coli and its function in ovarian cancer.

Wei Liu1, Lei Wang1, Jiajia Zhang1, Liuhui Qiao1, Yiqing Liu1, Xinke Yang1, Jinghua Zhang1, Wenming Zheng1, Zhenling Ma1.   

Abstract

Chemokine (CC-motif) ligand 2 (CCL2) is an inflammatory cytokine that regulates the infiltration and migration of monocytes. It is highly expressed by both tumor and stromal cells and has been associated with tumorigenesis. However, the effect of the exogenous administration of CCL2 on ovarian cancer remains largely unknown. In this report, we attempted to establish an expression system in Escherichia coli to produce recombinant hCCL2. The recombinant plasmid containing the hCCL2 cDNA was prepared using the prokaryotic-expression plasmid pGEX-5X-3 and transformed into E. coli BL21. GST-hCCL2 was successfully induced by 0.1 mmol/L IPTG at 20 °C for 6 h, and the recombinant protein was purified using affinity chromatography. The purified protein was identified by SDS-PAGE and Western Blot. In vitro experiments revealed that rhCCL2 promoted the proliferation of ovarian cancer cells and increased the levels of phosphorylation of MEK and ERK1/2, and the levels of JUN, RELB and NF-κB2 mRNA. Furthermore, inhibition of ERK signaling by treatment with PD98059 decreased ovarian cancer cell proliferation and levels of JUN, RELB, and NF-κB2 mRNA, indicating that exogenous rhCCL2 increased the proliferation of ovarian cancer cells, partially by activating the MAPK/ERK pathway, and by targeting JUN, RELB, and NF-κB2. Our study uncovered a promoting role of exogenous CCL2 on ovarian cancer cell proliferation through the MAPK/ERK signaling pathway, which may facilitate the discovery of more potential roles of CCL2 in ovarian cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13205-020-02571-0. © King Abdulaziz City for Science and Technology 2021.

Entities:  

Keywords:  Cell proliferation; Cell signaling pathway; Ovarian cancer cell; Protein purification; rhCCL2

Year:  2021        PMID: 33442507      PMCID: PMC7778648          DOI: 10.1007/s13205-020-02571-0

Source DB:  PubMed          Journal:  3 Biotech        ISSN: 2190-5738            Impact factor:   2.406


  35 in total

1.  Glycosylation enhances functional stability of the chemotactic cytokine CCL2.

Authors:  Paolo Ruggiero; Silvio Flati; Vito Di Cioccio; Giovanni Maurizi; Giovanni Macchia; Alberto Facchin; Roberto Anacardio; Antonio Maras; Marilena Lucarelli; Diana Boraschi
Journal:  Eur Cytokine Netw       Date:  2003 Apr-Jun       Impact factor: 2.737

2.  Purification of proteins fused to glutathione S-transferase.

Authors:  Sandra Harper; David W Speicher
Journal:  Methods Mol Biol       Date:  2011

3.  Expression, purification, and therapeutic implications of recombinant sFRP1.

Authors:  Archita Ghoshal; Siddhartha Sankar Ghosh
Journal:  Appl Biochem Biotechnol       Date:  2014-11-30       Impact factor: 2.926

Review 4.  Overview of Fusion Tags for Recombinant Proteins.

Authors:  E N Kosobokova; K A Skrypnik; V S Kosorukov
Journal:  Biochemistry (Mosc)       Date:  2016-03       Impact factor: 2.487

Review 5.  Inflammation and ovarian cancer.

Authors:  Antonio Macciò; Clelia Madeddu
Journal:  Cytokine       Date:  2012-02-19       Impact factor: 3.861

6.  Purification of GST-Tagged Proteins.

Authors:  Frank Schäfer; Nicole Seip; Barbara Maertens; Helena Block; Jan Kubicek
Journal:  Methods Enzymol       Date:  2015-05-16       Impact factor: 1.600

7.  Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study.

Authors:  Franco Berrino; Roberta De Angelis; Milena Sant; Stefano Rosso; Magdalena Bielska-Lasota; Magdalena B Lasota; Jan W Coebergh; Mariano Santaquilani
Journal:  Lancet Oncol       Date:  2007-09       Impact factor: 41.316

8.  Biochemical and biologic characterization of murine monocyte chemoattractant protein-1. Identification of two functional domains.

Authors:  C A Ernst; Y J Zhang; P R Hancock; B J Rutledge; C L Corless; B J Rollins
Journal:  J Immunol       Date:  1994-04-01       Impact factor: 5.422

9.  Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients.

Authors:  L Hefler; C Tempfer; G Heinze; K Mayerhofer; G Breitenecker; S Leodolter; A Reinthaller; C Kainz
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

Review 10.  CCL2/Monocyte Chemoattractant Protein 1 and Parathyroid Hormone Action on Bone.

Authors:  Jawed Akhtar Siddiqui; Nicola C Partridge
Journal:  Front Endocrinol (Lausanne)       Date:  2017-03-29       Impact factor: 5.555

View more
  2 in total

Review 1.  Proper animal experimental designs for preclinical research of biomaterials for intervertebral disc regeneration.

Authors:  Yizhong Peng; Xiangcheng Qing; Hongyang Shu; Shuo Tian; Wenbo Yang; Songfeng Chen; Hui Lin; Xiao Lv; Lei Zhao; Xi Chen; Feifei Pu; Donghua Huang; Xu Cao; Zengwu Shao
Journal:  Biomater Transl       Date:  2021-06-28

Review 2.  CC Chemokine Ligand-2: A Promising Target for Overcoming Anticancer Drug Resistance.

Authors:  Zhenbo Shi; Jian Tu; Ying Ying; Yunlian Diao; Ping Zhang; Shu Liao; Zhijuan Xiong; Shibo Huang
Journal:  Cancers (Basel)       Date:  2022-08-31       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.